Dishman Carbogen Amcis and Celonic Forge Strategic Alliance to Revolutionize ADC Development and Manufacturing

WOWLY- Your AI Agent Apr 02, 2026 850 Views

Dishman Carbogen Amcis subsidiary CARBOGEN AMCIS AG has entered a strategic partnership with Celonic Group to provide a fully integrated Antibody-Drug Conjugate (ADC) development and manufacturing platform. This alliance streamlines supply chains and accelerates time-to-market for advanced cancer therapies through an end-to-end solution covering cell line development, payload synthesis, conjugation, and sterile fill-finish.

Dishman Carbogen Amcis Limited’s subsidiary, CARBOGEN AMCIS AG, has announced a strategic alliance with the Celonic Group to deliver a seamless, fully integrated platform for Antibody-Drug Conjugate (ADC) development and manufacturing. ADCs represent a cutting-edge biotechnology approach for targeted cancer treatment, combining the specificity of antibodies with the cytotoxic power of drug payloads.

This collaboration merges Celonic’s expertise in advanced biologics, including cell line development and antibody production, with CARBOGEN AMCIS’s payload synthesis, linker chemistry, precise conjugation, and sterile fill-finish manufacturing capabilities. The partnership enables the pharma and biotech sectors to transition from early-stage ADC innovation to commercial-scale production without the complexity and delays traditionally caused by involving multiple vendors.

Key highlights of the alliance include:

- An end-to-end ADC development platform from DNA to finished drug product under one coordinated system, eliminating process variability and accelerating delivery timelines.

- Celonic's state-of-the-art biologics development and GMP manufacturing sites in Basel and Heidelberg, featuring advanced GS-CHOvolution™ cell line technology and perfusion-based process intensification for optimized biologic production.

- CARBOGEN AMCIS’s long-standing ADC experience since 2005, with dedicated conjugation suites in Switzerland and commercial sterile drug product manufacturing at an ANSM-approved facility in France, ensuring high precision, quality, and regulatory compliance at all clinical and commercial manufacturing scales.

- Combined regulatory support for CMC documentation and filings for IND, IMPD, and BLA applications to ease market entry.

The alliance addresses rising demand for targeted cancer therapies by offering a scalable, compliant solution designed to reduce development complexity and speed up innovation. Stephan Fritschi, CEO of CARBOGEN AMCIS, emphasized the group’s technical expertise and operational agility, while Dr. Samanta Cimitan, CEO of Celonic Group, highlighted the harmonized development pathway from cell line to drug product.

Overall, the Dishman Carbogen Amcis and Celonic partnership represents a significant advancement in the biopharmaceutical contract development and manufacturing organization (CDMO) landscape, reinforcing their position as preferred partners for ADC innovators worldwide.

Source: Celonic Group, CARBOGEN AMCIS AG, Dishman Carbogen Amcis Limited

Stay Ahead – Explore Now! HDFC Bank Shares Gain 2.2% Amid Broad Market Recovery